HIV-1 reverse transcriptase thumb subdomain polymorphisms associated with virological failure to nucleoside drug combinations

Journal of Antimicrobial Chemotherapy

Volumn 64, Issue 2, 2009, Pages 251-258

  Garriga, César ^a,i   Pérez Elías, María Jesús ^b   Delgado, Rafael ^c   Ruiz, Lidia ^d   Pérez Álvarez, Lucía ^e   Pumarola, Tomàs ^f   López Lirola, Ana ^g   González García, Juan ^h   Menéndez Arias, Luis ^a   Pedreira, J D ^j   Losada, E ^k   Prieto, A ^k   Agulla, A ^l   Marino A ^l   Lezaun, M J ^m   Agud, J M ^m   Blanco, J L ⁿ   Arnedo Valero, M ⁿ   Guila M ⁿ   Clotet, B ^d   Puig, T ^d   Cilla, G ^o   Echeverria J ^o   Rodriguez Arrondo F ^o   von Wichman, M A ^o   Iribarren, J A ^o   Arrizabalaga, J ^o   Rodriguez A ^p   Lopez Alvarez M J ^p   Corredoira, J ^p   Sanz, J ^q   Gutierrez F ^c   Pulido, F ^c   Rubio, R ^c   Zurita, M S ^c   Arribas Lopez J R ^h   Garcia Bujalance S ^h   Montero Vega, D ^h   Pena J M ^h   Garcia Arata I ^b   Gutierrez C ^b   Lopez Perez M D ^b   Galan J C ^b   Najera R ^e   Contreras, G ^e   Cuevas, L ^e   Pinilla, M ^e   Galindo Carretero, S ⁱ   Sanchez Alonso F ⁱ   Diz Aren J ^r   Ojea de Castro, R ^r   Rodriguez R ^r   Ocampo, A ^s   Miralles, C ^s   Perez Castro S ^t   Gomez Sirvent J L ^g   Alonso Socas, M M ^g   Aleman Valls M R ^g   Hernandez Calzadilla C ^g   Suarez D ^u   Cisterna, R ^u   Santamaria J M ^u   Munoz J ^u   Zubero, Z ^u   Baraia Etxaburu, J ^u   Ferrero, O ^u   Ibarra, S ^u   Corral, J M ^v   Aguirrebengoa, K ^v   Polo, R ^w   more..

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^b HOSPITAL RAMÓN Y CAJAL   (Spain)

^c HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^d HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^e INSTITUTO DE SALUD CARLOS III   (Spain)

^f HOSPITAL CLÍNIC   (Spain)

^g HOSPITAL UNIVERSITARIO DE CANARIAS   (Spain)

^h HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

ⁱ CARLOS III INSTITUTE OF HEALTH   (Spain)

^j HOSPITAL JUAN CANALEJO   (Spain)

^k HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^l Universidad de La Coruña   (Spain)

^m HOSPITAL TXAGORRITXU   (Spain)

ⁿ Hospital Clýínic   (Spain)

^o HOSPITAL DONOSTIA   (Spain)

^p HOSPITAL XERAL CALDE   (Spain)

^q Asturias University Hospital in Alcalá de Henares   (Spain)

^r HOSPITAL MONTECELO   (Spain)

^s Department of Neurosurgery   (Spain)

^t Hospital Mexoeiro   (Spain)

^u HOSPITAL DE BASURTO   (Spain)

^v HOSPITAL DE CRUCES   (Spain)

^w Secretaria del Plan Nacional sobre el Sida   (Spain)

more..

Author keywords

Abacavir; HIV; Resistance; Stavudine

Indexed keywords

ABACAVIR; DIDANOSINE; LAMIVUDINE; RIBONUCLEASE H; RNA DIRECTED DNA POLYMERASE; STAVUDINE; TENOFOVIR; THYMIDINE; ZIDOVUDINE;

AMINO ACID SUBSTITUTION; ARTICLE; CONTROLLED STUDY; DRUG TREATMENT FAILURE; GENETIC POLYMORPHISM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; NUCLEOTIDE SEQUENCE; VIRUS MUTATION;

ANTI-HIV AGENTS; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; MUTATION, MISSENSE; POLYMORPHISM, GENETIC; SEQUENCE ANALYSIS, DNA; TREATMENT FAILURE;

EID: 67650979706     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkp200     Document Type: Article

References (34)

1. Castro HC, Loureiro NIV, Pujol-Luz M et al. HIV-1 reverse transcriptase: A therapeutical target in the spotlight. Curr Med Chem 2006; 13: 313-24.
2. Basavapathruni A, Anderson KS. Reverse transcription of the HIV-1 pandemic. FASEB J 2007; 21: 3795-808.
3. De Clercq E. The design of drugs for HIV and HCV. Nat Rev Drug Discover 2007; 6: 1001-18.
4. Menéndez-Arias L. Mechanisms of resistance to nucleoside analogue inhibitors of HIV-1 reverse transcriptase. Virus Res 2008; 134 124-46.
5. Sluis-Cremer N, Tachedjian G. Mechanisms of inhibition of HIV replication by non-nucleoside reverse transcriptase inhibitors. Virus Res 2008; 134: 147-56.
6. Johnson VA, Brun-Vézinet F, Clotet B et al. Update of the drug resistance mutations in HIV-1: Spring 2008. Top HIV Med 2008; 16: 62-8.
7. Stürmer M, Staszewski S, Doerr H-W et al. Correlation of phenotypic zidovudine resistance with mutational patterns in the reverse transcriptase of human immunodeficiency virus type 1: Interpretation of established mutations and characterization of new polymorphisms at codons 208, 211 and 204. Antimicrob Agents Chemother 2003; 47 54-61.
8. Rhee S-Y, Fessel WJ, Zolopa AR et al. HIV-1 protease and reverse-transcriptase mutations: Correlations with antiretroviral therapy in subtype B isolates and implications for drug-resistance surveillance. J Infect Dis 2005; 192: 456-65.
9. Svicher V, Sing T, Santoro MM et al. Involvement of novel human immunodeficiency virus type 1 reverse transcriptase mutations in the regulation of resistance to nucleoside inhibitors. J Virol 2006; 80: 7186-98.
10. Cane PA, Green H, Fearnhill E et al. Identification of accessory mutations associated with high-level resistance in HIV-1 reverse transcriptase. AIDS 2007; 21: 447-55.
11. Ceccherini-Silberstein F, Svicher V, Sing T et al. Characterization and structural analysis of novel mutations in human immunodeficiency virus type 1 reverse transcriptase involved in the regulation of resistance to nonnucleoside inhibitors. J Virol 2007; 81: 11507-19.
12. Yahi N, Tamalet C, Tourrés C et al. Mutation patterns of the reverse transcriptase and protease genes in human immunodeficiency virus type 1-infected patients undergoing combination therapy: Survey of 787 sequences. J Clin Microbiol 1999; 37: 4099-106.
13. Marcelin A-G, Delaugerre C, Wirden M et al. Thymidine analogue reverse transcriptase inhibitors resistance mutations profiles and association to other nucleoside reverse transcriptase inhibitors resistance mutations observed in the context of virological failure. J Med Virol 2004; 72: 162-5.
14. Cozzi-Lepri A, Ruiz L, Loveday C et al. Thymidine analogue mutation profiles: Factors associated with acquiring specific profiles and their impact on the virological response to therapy. Antivir Ther 2005; 10: 791-802.
15. Nikolenko GN, Palmer S, Maldarelli F et al. Mechanism for nucleoside analog-mediated abrogation of HIV-1 replication: Balance between RNase H activity and nucleotide excision. Proc Natl Acad Sci USA 2005; 102: 2093-8.
16. Brehm JH, Koontz D, Meteer JD et al. Selection of mutations in the connection and RNase H domains of human immunodeficiency virus type 1 reverse transcriptase that increase resistance to 3′-azido-3′-dideoxythymidine. J Virol 2007; 81: 7852-9.
17. Hachiya A, Kodama EN, Sarafianos SG et al. Amino acid mutation N348I in the connection subdomain of human immunodeficiency virus type 1 reverse transcriptase confers multiclass resistance to nucleoside and nonnucleoside reverse transcriptase inhibitors. J Virol 2008; 82: 3261-70.
18. Yap S-H, Sheen C-W, Fahey J et al. N348I in the connection domain of HIV-1 reverse transcriptase confers zidovudine and nevirapine resistance. PLoS Med 2007; 4: 1887-900.
19. Ntemgwa M, Wainberg MA, Oliveira M et al. Variations in reverse transcriptase and RNase H domain mutations in human immunodeficiency virus type 1 clinical isolates are associated with divergent phenotypic resistance to zidovudine. Antimicrob Agents Chemother 2007; 51 3861-9.
20. Roquebert B, Marcelin A-G. The involvement of HIV-1 RNase H in resistance to nucleoside analogues. J Antimicrob Chemother 2008; 61: 973-5.
21. Ehteshami M, Beilhartz GL, Scarth BJ et al. Connection domain mutations N348I and A360V in HIV-1 reverse transcriptase enhance resistance to 3′-azido-3′-deoxythymidine through both RNase H-dependent and -independent mechanisms. J Biol Chem 2008; 283 22222-32.
22. Garriga C, Pérez-Elías MJ, Delgado R et al. Mutational patterns and correlated amino acid substitutions in the HIV-1 protease after virological failure to nelfinavir- and lopinavir/ritonavir-based treatments. J Med Virol 2007; 79: 1617-28.
23. Garriga C, Menéndez-Arias L. DR_SEQAN: A PC/Windows-based software to evaluate drug resistance using human immunodeficiency virus type 1 genotypes. BMC Infect Dis 2006; 6: 44.
24. Wu TD, Schiffer CA, Gonzales MJ et al. Mutation patterns and structural correlates in human immunodeficiency virus type 1 protease following different protease inhibitor treatments. J Virol 2003; 77: 4836-47.
25. Benjamini Y, Hochberg Y. Controlling the false discovery rate: A practical and powerful approach to multiple testing. J R Stat Soc Ser B 1995; 57; 289-300.
26. Menéndez-Arias L, Domingo E. Amino acid substitutions associated with resistance to HIV-1 reverse transcriptase inhibitors, protease inhibitors, and other drugs targeting virus maturation. In: Clotet B, Menéndez-Arias L, Schapiro JM et al., eds. Guide to Management of HIV Drug Resistance, Antiretrovirals Pharmacokinetics and Viral Hepatitis in HIV Infected Subjects, Eighth Edition. Barcelona: Fundació de Lluita contra la SIDA, 2008; 37-128.
27. Rhee S-Y, Liu TF, Holmes SP, Shafer RW. HIV-1 subtype B protease and reverse transcriptase amino acid covariation. PLoS Comp Biol 2007; 3: E87.
28. Nebbia G, Sabin CA, Dunn DT et al. Emergence of the H208Y mutation in the reverse transcriptase (RT) of HIV-1 in association with nucleoside RT inhibitor therapy. J Antimicrob Chemother 2007; 59: 1013-6.
29. Bebenek K, Beard WA, Darden TA et al. A minor groove binding track in reverse transcriptase. Nat Struct Biol 1997; 4: 194-7.
30. Ding J, Das K, Hsiou Y et al. Structure and functional implications of the polymerase active site region in a complex of HIV-1 RT with a double-stranded DNA template-primer and an antibody Fab fragment at 2.8 Å resolution. J Mol Biol 1998; 284: 1095-111.
31. Bebenek K, Beard WA, Casas-Finet JR et al. Reduced frame-shift fidelity and processivity of HIV-1 reverse transcriptase mutants containing alanine substitutions in helix H of the thumb subdomain. J Biol Chem 1995; 270: 19516-23.
32. Powell MD, Beard WA, Bebenek K et al. Residues in the αH and αI helices of the HIV-1 reverse transcriptase thumb subdomain required for the specificity of RNase H-catalyzed removal of the polypurine tract primer. J Biol Chem 1999; 274: 19885-93.
33. Nikolenko G, Delviks-Frankenberry KA, Palmer S et al. Mutations in the connection domain of HIV-1 reverse transcriptase increase 3′-azido-3′-deoxythymidine resistance. Proc Natl Acad Sci USA 2007; 104: 317-22.
34. Delviks-Frankenberry KA, Nikolenko G, Barr R, Pathak VK. Mutations in human immunodeficiency virus type 1 RNase H primer grip enhance 3′-azido-3′-deoxythymidine resistance. J Virol 2007; 81: 6837-45.